Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of dostarlimab in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
NL-OMON58029Recruiting
- Sponsor
- GSK
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dostarlimab in rectal cancer, sponsored by GSK. Primary endpoints: Percentage of participants who maintain real-world complete clinical response for 12 months and Percentage of participants who maintain combined complete clinical and pathological response for 12 months. Started Apr 2026; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON58029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58029.